Use of a phosphorus-enriched hemodialysate to prevent hypophosphatemia in a patient with renal failure-related pericarditis.
We describe a patient who suffered from renal failure-associated pericarditis and underwent daily 3.5-hour hemodialysis treatments for 17 days. The initially elevated serum phosphorus level gradually fell to below normal on days 11 and 12 as a result of the intensive dialytic therapy. Phosphorus was added to the "base concentrate" of a dual-concentrate, bicarbonate-based dialysate delivery system on days 13 to 17. Because of this phosphorus-enrichment, we were able to maintain the patient's serum phosphorus levels within normal limits in spite of continued daily dialysis treatments.
Emelife-Obi
C
C
Department of Medicine, Veterans Affairs Hospital, Hines, Illinois 60141, USA.
Chow
M T
MT
Qamar-Rohail
H
H
Leehey
D J
DJ
Gandhi
V C
VC
Ing
T S
TS
D015312:Hemodialysis Solutions / Q000737:chemistry*; D006801:Humans; D017674:Hypophosphatemia / Q000517:prevention & control*; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008875:Middle Aged; D010493:Pericarditis / Q000209:etiology*; D010758:Phosphorus / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D006435:Renal Dialysis
D015312:Hemodialysis Solutions; D010758:Phosphorus